Vancouver-based Filament Health, a natural psychedelic drug development company, has expanded the scope of its research.
The company was already federally licensed to work with psychoactive mushrooms, but an amendment to its Health Canada Dealer’s Licence will now allow Filament to possess, produce, research, export and import all remaining controlled natural psychedelic substances, including N,N-dimethyltryptamine (DMT) and mescaline.
“This licence amendment significantly increases the scope of our work with natural psychedelics,” said Filament’s director of research, Ryan Moss. “By studying untapped psychedelics in a scientific setting, we believe we can unlock and standardize their healing power. This is a promising step forward in our mission to get safe, natural psychedelics into the hands of everyone who needs them, as soon as possible,” Moss said.
Filament plans to produce natural extracts of these substances at its facility in Metro Vancouver and enter them
Read full article on The Growth Op